Genmab A/S (GNMSF) EPS (Basic) (2018 - 2026)
Genmab A's (GNMSF) quarterly EPS (Basic) came in at $87.79 in Q1 2026, up 9.64% YoY from $80.07 in Q1 2025, and up 0.96% on a QoQ basis from $86.95 in Q3 2025.
Genmab A/S (GNMSF) EPS (Basic) (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 6 years of EPS (Basic) data on file, last reported at $87.79 in Q1 2026.
- Quarterly EPS (Basic) rose 9.64% year-over-year to $87.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.85 (up 16.65% YoY) and the FY2025 annual result came in at $14.88, down 80.84% from the prior year.
- EPS (Basic) rose to $87.79 in Q1 2026, from $86.95 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $87.79 in Q1 2026 to a low of -$0.04 in Q4 2024.
- A 3-year average of $51.6 and a median of $71.99 in 2024 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2025 — EPS (Basic) soared 34.2% — and 2026, when it increased 9.64%.
- Tracing GNMSF's EPS (Basic) over 3 years: stood at -$0.04 in 2024, then surged by 197728.87% to $86.95 in 2025, then climbed by 0.96% to $87.79 in 2026.
- The last three EPS (Basic) figures came in at $87.79 (Q1 2026), $86.95 (Q3 2025), and $8.03 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68 |
| Mar 31, 2026 | 87.79 |
| Sep 30, 2025 | 86.95 |
| Jun 30, 2025 | 8.03 |
| Mar 31, 2025 | 80.07 |
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | 72.60 |
| Jun 30, 2024 | 5.98 |
| Mar 31, 2024 | 71.38 |
| Sep 30, 2020 | 0.00 |
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 11.39 |
| Dec 31, 2018 | 0.00 |